Chemist Wendy Shaw, a nationally recognized scientific leader, has been chosen to serve as the associate laboratory director for PNNL's Physical and Computational Sciences Directorate.
The Pacific Northwest Association of Toxicologists (PANWAT) presented its annual Toxicology Achievement Award to Katrina Waters at the Society of Toxicology Pacific Northwest Chapter Meeting, held in Lynnwood, Washington, on September 30th.
PNNL biodefense experts seek to identify, understand and mitigate the risks of biological pathogens—whether naturally occurring or intentionally created—so steps can be taken to prepare and respond.
PNNL researchers are exploring the kinds of flicker waveforms that the eye and brain can detect, seeking to understand the different visual and non-visual effects that result.
Early life exposure to polycyclic aromatic hydrocarbons (PAHs), found in smoke, has been linked to developmental problems. To study the impacts of these pollutants, PAH metabolism in infants and adults were compared.
Three PNNL-affiliated researchers have been named fellows of the American Association for the Advancement of Science, the world’s largest multidisciplinary scientific society.
GUV can reduce transmission of airborne disease while reducing energy use and carbon emissions. But fulfilling that promise depends on having accurate and verifiable performance data.
Researchers investigated how stable nanoparticle suspensions form using facet engineering on hematite nanoparticles, demonstrating that controlling the faceting of nanoparticles can effectively maintain particle dispersity.
Mandy Mahoney, director of the DOE Building Technologies Office, visited PNNL in late November. One key agenda item involved meeting with staff for a discussion of effective equity and justice integration in buildings-related research.
PNNL’s Andrea Mengual co-chaired a working group that produced Building Performance Standards: A Technical Resource Guide. PNNL’s Kim Cheslak, Bing Liu, and Jian Zhang contributed to the effort.
Scientists screen for nanobodies that recognize wild type and mutant functional proteins to develop a framework to disrupt protein interactions that can cause disease.
